Nosocomial pneumonia (NP) -is a disease associat ed with a formation of new focal and infiltrative changes on the chest X ray 48 hrs after the hospitalization along with the clinical data confirming their infectious nature (fever, purulent sputum or purulent discharge from the tracheo bronchial tree, leukocytosis, etc.), excluding infections which were incubated on the admission [1] .
geal, esophageal and stomach contents is the leading factor in NP pathogenesis. The risk of aspiration significantly increases in conscious impairment, dysphagia, deteriora tion of pharyngeal reflexes and intestinal peristalsis, in intubated patients. Tracheal intubation makes a way for bacterial migration into lungs. Bacterial biofilms formation occurs inside the tracheal tubes. Microbes in the biofilms are protected against antibiotics and immune system. Translocation of opportunistic microbes from the intestines is the other important pathogenetic factor of NP. Exogenous acquisition of NP may occur from the air, med ical gases, respiratory devices, microbiota of medical per sonnel and other patients etc. [6] [7] [8] The proved methods of NP prophylaxis in the inten sive care unit include the 300 elevation of head, an early removal of nasogastric tubes, a continuous subglottic aspiration and a regular oral cleaning with watery chlorhexidine [8] .
The key etiological agents of NP are cassociations of multiresistant gram negative (Pseudomonas aerugi nosa, Acinetobacter spp., Klebsiella pneumonia) and gram positive (Staphylococcus aureus) strains. The spectrum of NP agents differs among the intensive care units. Associations of 3-4 multiresistant strains of Pseudomonas aeruginosa (70-80%), Acinetobacter bau manii/calcoaceticus (70-90%), Klebsilella pneumonia (30-40%), Proteus mirabilis (20-25%) were detected in our investigation; gram positive strains were detected in 10-15% of patients (Staphylococcus aureus MRSA, Enterococcus faecalis, Enterococcus faecium) [9] [10] [11] [12] [13] .
Rational antibiotic therapy is the background of NP treatment. Intravenous carbapenems, cephalosporins III-IV generations, protected anti pseudomonal penicillines, aminoglycosides, fluoroquinolones, glycopeptides and their combinations are recommended for NP treatment [9] . Early start of antibiotics improves outcomes, but the mortality and microbial resistance still remain extremely high. The prob lem of microbial resistance to the majority of antibiotics is of great significance. Pseudomonas aeruginosa, Acinetobacter spp., Burkholderia spp., Stenotrophomonas spp., have a natur al property to form biolayers, which protect them against the immune system and antibiotics. There are currently no per spectives of producing new classes of antibiotics [8] [9] .
In view of the abovementioned special regimens of antibiotic therapy are recommended: increase of doses, con tinuous infusions, etc. Randomized controlled trial shows that continuous infusion of piperacillin/tazobactam and carbapenems decreases the mortality in NP. The main pit fall of intravenously administered antibiotics is their bad penetration into the lungs, which leads to the sputum con centrations lower than bectericidial. Increasing daily doses of antibiotics is related to a risk of selection of multiresis tant strains, side effects and superinfection. Theferore inhaled antibiotics (IA) as an adjunct to systemic ones pre sent a good treatment modality [7, 9, [14] [15] .
Inhaled antibiotics
The inhaled root has long been used to administer various medicines: antibiotics, antifungals, antimycobacte rials, immune supressors, insulin, vaccines, nitrous oxide, interferones, furosemide, in genotherapy of some diseases. Ehrmann S. et al. showed that 99% of German doctors use some inhaled preparations, 43% of them use nebulizers (55% -jet, 44% -ultrasound, 14% -mesh nebulizers). Eighty percent of them use inhaled colistin in their daily practice, and 30% use inhaled antibiotics minimum 2 times a year [16] . 
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Inhaled antibiotics in modern medicine [22]
Inhaled colistin, tobramycin, cephalosporins, ampho tericin B, pentamydin have been used for prophylaxis and treatment of various infections for more than 50 years now. Modern nebulizers help to administer nearly 50-70% of IA dose directly into the infection focus. It is noteworthy that in this case the local sputum concentration of antibiotics is significantly higher that after the intravenous administra tion, which is important when treating multiresistant strains and preventing the formation of resistance. Inhaled administration of antibiotics is related to less systemic tox icity and a profound action on biolayers [17] [18] [19] [20] [21] [22] .
Inhaled colistin and inhaled aminoglycosides are the most frequently used IA in pulmonology and inten sive care medicine [11] [12] [13] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Aminoglycosides are the most suitable antibiotics for inhalation because they are bactericidial and concentration dependant (high concentration for a short period of time) [29] [30] [31] [32] . Also inhaled fluoroquinolones [40] , cephalosporines [41] , lipo somal aminoglycosides [42] ; aztreonam [43] , combina tions (fosfomycin/tobramycin, colitin/tobramycin, ciprofloxacin/colistin) [44] [45] are used. Inhaled fos fomycin is active against both gram negatives and gram positives, but it is strongly recommended to combine it with other antibiotics to prevent a rapid resistance for mation [46] . It is inexpedient to use inhaled beta lac tames, because they are concentration dependant antibi otics, and therefore multiple inhalations will be required (e.g. every 3 hrs for ceftazidime). Carbapenems when inhaled induce allergic reaction: inhaled doripenem study was stopped at stage one due to this reason [20] [21] 47] . Table deals with the currently used IA [22] .
The majority of IA are used to treat acute and chron ic pseudomonal infection in cystic fibrosis and bron choectatic disease. Chronic preudomonal infection in cys tic fibrosis increases mortality. Inhaled tobramycin (IT), colistin (50-75 mg BID TID), aztreonam (75 mg TID within 28 days) and other antibiotics are used for continu ous treatment of infectious complications of cystic fibrosis both in and out hospital. A 28 day course of IT is proved to be effective in eradication of Pseudomonas aeruginosa in cystic fibrosis (300 mg/day within 28 days, then 28 days break). But the recent meta analysis shows that there are currently no evident data to support IA use in cystic fibro sis. Moreover, the increase of the prevalence of colistin and aminoglycoside resistant strains of Pseudomonas aerugi nosa and gram positive microbes is detected in cystic fibro sis patients [27-30, 32-33, 36, 48] .
There were no randomized multicenter trials of IA use in NP. Several small trials proved that IA in combina tion with systemic antibiotics decrease the symptoms of NP, facilitate weaning from ventilator, decrease the sputum microbes titer. There are also some data on IA efficacy in nosocomial tracheobronchitis. Lu Q. et al. showed the same efficacy of systemic and inhaled ceftazidime and amikacin, but a lower rate of resistance formation in IA groups. It is noteworthy that IA in this study were used as a monother apy (ceftazidime 15 mg/kg every 3 hrs., amikacin 25 mg/kg/day). Several cases of exhalation filter obstruction were detected [41] . The same group of authors proved later the same efficacy of inhaled colistin and combination of intravenous beta lactames and aminoglycosides in NP patients caused by Pseudomonas aeruginosa and Acinetobacter baumanii [49] . Korbila I. et al. showed more rapid NP resolution in combination of inhaled and intra venous forms of colistin [23] . Arnold H. et al. in the retro spective trial showed a higher survival in NP patients treat ed with IT [31] . All the abovementioned trials showed a low threshold of resistance emergence and low incidence of side effects in IA use.
Our data on the inhaled tobramycin use in septic patients with NP proved its efficacy and safety: decrease of systemic inflammation and acute respiratory insufficiency signs 2,3±1,2 after the treatment onset. Eradication of microbes in sputum was detected in 28% of patients, in other patients a decrease of microbial titer to 10 3 4 CFU/ml was detected. Deescalation of antibiotic therapy was possi ble in 20% of patients treated with IT. It is noteworthy that 20% of patients were in vitro resistant to tobramycin, but it was clinically effective, probably due to a local supercon centration. Treatment with IT was associated with an increase of sensitivity of microbes to antibiotics they were prior resistant to (40% of patients). This is probably due to IT effects on biolayers. Positive chest X ray dynamics was detected in 60% of patients 9,0±2,5 days after the treatment onset. The treatment with IT made it possible to wean 30% of patients on the day 5,2±1,7. Hearing loss and tinnitus was detected only in 2 patients in our study. There were no cases of bronchospasm or kidney dysfunction in our study, which is in accordance with the other trials [11] [12] [13] .
Only special preparations for inhalation and modern nebulizers must be used for an effective treatment with IA. The preparation for inhalation use should not contain some conservatives and should not be hyperosmolar, should be pH neutral and contain chlorides to prevent bronchospasm and cough [22] . Mesh nebulizers are most suitable for IA administration. This type of nebulizers forms 2.1 μm parti cles and provides a delivery of 5-70% of drug dose into the lungs; temperature of preparation remains constant during the aerosol formation; the air flow minimally affects the ventilation parameters; constant humidification of air can be continued. Instillation of antibiotics through the intu bation or tracheostomic tube is ineffective and must never be used [22] .
Inhaled antibiotics are not used as a monotherapy without the systemic antibiotics, because their absorbtion into the blood is low (2-4%) and not sufficient to treat the concomitant extrapulmonary infections and moreover insufficient to reach the alveoli [19] [20] [21] [22] 50] . But we have a clinical experience of an effective monotherapy with IT in a patient with severe allergic reaction to systemic antibiotics. Currently it is not recommended to use IA for the NP pro phylaxis [22, [50] [51] .
Use of IA is related to some problems. The penetra tion of IA into the obstructed airways is deteriorated. A pos sible inactivation of IA in sputum should be taken into account. This effect is mostly profound in aminoglycosides. A 25 fold increase over the minimal inhibitory concentra tion is required to overcome this inactivation. Changes of physico chemical properties of IA during the aerosol forma tion due to heating, cooling, vibration, etc. (more profound in jet nebulizers), local and systemic toxic effects, bron choconstrictive effects of conservatives should be noted. The bronchospasm is mostly induced by the inhaled colistin. Only special preparations for inhalation must be used to prevent these complications. Inhaled antibiotics and nebu lizers are expensive, their use is associated with the environ ment pollution and resistance formation [22, 50] .
Formation of microbial resistance is still a problem, but as it has been mentioned, the rate of resistance forma tion is lower in IA than in intravenous antibiotics. The informativity of sputum microbiology decreases in IA use: the absence of microbes in sputum does not mean their absence in distal parts of tracheobronchial tree and in alve oli. There are currently no inhaled anti gram positive antibiotics [22, 50] .
Thus, the use of IA in combination with the intra venous administration is an efficient and safe treatment modality for severe NP caused by gram negative strains. In spite of low evidence for this treatment method, the current situation of high microbial resistance and no perspectives of new antibiotics development rises the significance of this treatment modality.
